Want to see AEON full AI Analyst Report?
Top Page
AEON Biopharma
(AEON)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.28
▲(12.40% Upside)
Action:Reiterated
Date:08/01/26
The score is pressured primarily by weak financial performance (no revenue, recurring losses, cash burn, and negative equity) and a clearly bearish technical trend (price below all key moving averages). Valuation provides limited support due to negative earnings and no dividend, while recent financing modestly improves liquidity but adds dilution risk.
Positive Factors
Improved liquidity from equity offering
The recent equity offering added roughly $1.4M net proceeds, materially easing near-term financing pressure. This bolsters the company’s capital base to fund clinical programs and regulatory activities over the coming months, extending runway for milestone-driven value creation.
Negative Factors
No revenue and sizable recurring losses
The company generates no operating revenue and reported a TTM net loss around $60.1M, leaving it wholly reliant on financings. Persistent losses erode capital, force repeated dilution or debt raises, and constrain the ability to scale operations absent successful clinical outcomes or partner funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved liquidity from equity offering
The recent equity offering added roughly $1.4M net proceeds, materially easing near-term financing pressure. This bolsters the company’s capital base to fund clinical programs and regulatory activities over the coming months, extending runway for milestone-driven value creation.
Read all positive factors
AEON Biopharma (AEON) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.27M
Dividend YieldN/A
Average Volume (3M)273.24K
Price to Earnings (P/E)―
Beta (1Y)1.43
Revenue GrowthN/A
EPS Growth-101.45%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.03
Shares Outstanding44,158,810
10 Day Avg. Volume605,674
30 Day Avg. Volume273,237
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.63
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.00Price Target Upside300.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.05
Revenue Forecast (FY)N/A
AEON Biopharma Business Overview & Revenue Model
Company Description
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botuli...
How the Company Makes Money
null...
AEON Biopharma Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
6
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -19.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -24.07M | -16.22M | -27.73M | -52.74M | -52.49M | -36.88M |
| Net Income | -60.11M | -39.22M | 42.01M | -384.63M | -52.56M | -55.64M |
Balance Sheet | ||||||
| Total Assets | 8.63M | 5.56M | 3.14M | 6.84M | 10.78M | 6.44M |
| Cash, Cash Equivalents and Short-Term Investments | 6.24M | 3.01M | 13.00K | 5.16M | 9.75M | 5.13M |
| Total Debt | 2.63M | 35.74M | 12.96M | 278.00K | 131.53M | 86.89M |
| Total Liabilities | 25.38M | 60.59M | 31.71M | 159.89M | 281.19M | 230.26M |
| Stockholders Equity | -16.75M | -55.03M | -28.57M | -153.04M | -287.50M | -234.94M |
Cash Flow | ||||||
| Free Cash Flow | -12.04M | -17.31M | -20.29M | -47.83M | -35.89M | -28.60M |
| Operating Cash Flow | -12.04M | -17.31M | -20.29M | -47.83M | -35.58M | -28.43M |
| Investing Cash Flow | 0.00 | -4.00K | 0.00 | 0.00 | -306.00K | -170.00K |
| Financing Cash Flow | 7.83M | 20.30M | 15.15M | 14.00M | 40.51M | 13.56M |
AEON Biopharma Technical Analysis
Negative
0.25
Price Trends
0.58
Negative
0.78
Negative
0.90
Negative
Market Momentum
-0.13
Positive
18.00
Positive
5.97
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AEON, the sentiment is Negative. The current price of 0.25 is below the 20-day moving average (MA) of 0.37, below the 50-day MA of 0.58, and below the 200-day MA of 0.90, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 18.00 is Positive, neither overbought nor oversold. The STOCH value of 5.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AEON.
AEON Biopharma Risk Analysis
AEON Biopharma disclosed 61 risk factors in its most recent earnings report. AEON Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AEON Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $5.56M | -0.09 | -99.39% | ― | ― | 95.40% | |
47 Neutral | $6.72M | -0.27 | -341.23% | ― | ― | 71.83% | |
42 Neutral | $11.27M | -0.06 | 223.66% | ― | ― | -101.45% | |
39 Underperform | $6.18M | -0.82 | -269.02% | ― | ― | ― |
* Healthcare Sector Average
AEON
AEON Biopharma
0.29
-0.43
-59.31%
IMNN
Imunon
1.59
-6.41
-80.12%
XTLB
XTL Biopharmaceuticals Sponsored ADR
2.82
-4.02
-58.77%
RNAZ
TransCode Therapeutics
4.56
-6.84
-60.00%
AEON Biopharma Corporate Events
Business Operations and StrategyPrivate Placements and Financing
AEON Biopharma boosts liquidity with additional share sale
Positive
Jul 23, 2026
On July 15, 2026, AEON Biopharma, Inc. completed a public equity offering and, on July 23, 2026, sold an additional 4,696,102 shares of Class A common stock through a partial exercise of the underwriters’ over-allotment option, generating ap...
Executive/Board ChangesShareholder Meetings
AEON Biopharma shareholders approve directors and auditor slate
Positive
Jun 17, 2026
AEON Biopharma, Inc. held its Annual Meeting of Stockholders on June 17, 2026, at which shareholders elected Marc Forth and Seongsoo Park as Class III directors to serve three-year terms expiring at the 2029 annual meeting. Shareholders also ratif...
Business Operations and StrategyRegulatory Filings and Compliance
AEON Biopharma Releases Updated Investor Relations Presentation
Neutral
May 14, 2026
On May 14, 2026, AEON Biopharma, Inc. made a new corporate presentation available in the investor relations section of its website, which management may also use in future meetings with investors and other stakeholders. The company emphasized that...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.